Table 1 AAU Flare reported in the included RCTs
Study (ref) | Treatment | Placebo | ||||||
|---|---|---|---|---|---|---|---|---|
| Â | Treatment | Study duration (weeks) | Patients (n) | Uveitis (n) | Incidence (per 100 PY) | Patients (n) | Uveitis (n) | Incidence (per 100 PY) |
Van der Heijde D et al. 2006 [23] | ADA | 24 | 208 | 0 | 0.00 | 107 | 0 | 0.00 |
Sieper J et al. 2012 [24] | ADA | 12 | 95 | 0 | 0.00 | 97 | 0 | 0.00 |
Huang F et al. 2013 [25] | ADA | 12 | 229 | 0 | 0.00 | 115 | 0 | 0.00 |
Landewé R et al. 2013 [27] | CTZ | 24 | 218 | 2 | 1.98 | 107 | 3 | 6.07 |
Deodhar A et al. 2019 [28] | CTZ | 52 | 159 | 4 | 2.51 | 158 | 8 | 5.06 |
Inman R et al. 2008 [29] | GOL | 24 | 278 | 0 | 0.00 | 77 | 0 | 0.00 |
Deodhar A et al. 2017 [32] | GOL | 16 | 105 | 0 | 0.00 | 103 | 2 | 6.31 |
Sieper J et al. 2015 [31] | GOL | 16 | 97 | 0 | 0.00 | 100 | 0 | 0.00 |
Bao C et al. 2014 [30] | GOL | 24 | 169 | 1 | 1.28 | 44 | 0 | 0.00 |
Van der Heijde D et al. 2005 [34] | IFX | 18 | 202 | 0 | 0.00 | 75 | 0 | 0.00 |
Barkham N et al. 2009 [36] | IFX | 16 | 20 | 0 | 0.00 | 20 | 0 | 0.00 |
Inman R et al. 2010 [37] | IFX | 12 | 39 | 0 | 0.00 | 37 | 0 | 0.00 |
Marzo-Ortega H et al. 2005 [35] | IFX | 30 | 28 | 1 | 6.19 | 14 | 0 | 0.00 |
Sieper J et al. 2012 [38] | IFX | 28 | 105 | 0 | 0.00 | 52 | 0 | 0.00 |
Braun J et al. 2002 [33] | IFX | 12 | 34 | 1 | 12.74 | 35 | 3 | 37.14 |
Gorman JD et al. 2002 [40] | ETN | 16 | 20 | 0 | 0.00 | 20 | 0 | 0.00 |
Davis JC et al. 2003 [41] | ETN | 24 | 138 | 3 | 4.71 | 139 | 8 | 12.47 |
Brandt J et al. 2003 [42] | ETN | 6 | 14 | 0 | 0.00 | 16 | 0 | 0.00 |
Calin A et al. 2004 [43] | ETN | 12 | 45 | 0 | 0.00 | 39 | 0 | 0.00 |
Van der Heijde D et al. 2006 [44] | ETN | 12 | 305 | 0 | 0.00 | 51 | 1 | 8.49 |
Barkham N et al. 2010 [45] | ETN | 12 | 15 | 0 | 0.00 | 17 | 0 | 0.00 |
Dougados M et al. 2011 [46] | ETN | 12 | 39 | 0 | 0.00 | 43 | 0 | 0.00 |
Dougados M et al. 2014 [48] | ETN | 8 | 42 | 0 | 0.00 | 48 | 0 | 0.00 |
Dougados M et al. 2014 [47] | ETN | 12 | 106 | 0 | 0.00 | 109 | 0 | 0.00 |
Deodhar A et al. 2019 [54] | IXE | 16 | 212 | 5 | 7.66 | 104 | 0 | 0.00 |
Van der Heijde D et al. 2018 [26] | IXE | 16 | 164 | 1 | 1.98 | 86 | 0 | 0.00 |
Deodhar A et al. 2019 [55] | IXE | 52 | 198 | 3 | 2.09 | 104 | 2 | 1.92 |
Baeten D et al. 2013 [49] | SEC | 28 | 24 | 0 | 0.00 | 6 | 0 | 0.00 |
Baeten D et al. 2015 [50] | SEC | 16 | 394 | 7 | 5.77 | 196 | 2 | 3.31 |
Pavelka K et al. 2017 [51] | SEC | 16 | 150 | 0 | 0.00 | 75 | 0 | 0.00 |
Kivitz A et al. 2018 [52] | SEC | 16 | 233 | 0 | 0.00 | 117 | 0 | 0.00 |
Deodhar A et al. 2019 [53] | SEC | 52 | 369 | 7 | 1.21 | 186 | 2 | 1.07 |
Giardina A et al. 2010 [39] | IFX | 104 | 25 | 1 | 2.00 | - | - | - |
ETN | 25 | 2 | 4.00 | - | - | - | ||